Report Description

The global minimal residual disease (MRD) testing market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing occurrences of blood related cancer, growing awareness among physicians and consumers and extensive development in technology are fueling the growth of the market. Minimal Residual Disease (MRD) are basically term given to small numbers of cancer cells that are left in the patient during or after treatment when the patient is in remission. It is the main cause of relapse in cancer and leukemia. The other factors supporting the market’s growth are, rise in R&D activities, growing number of patients with cancer, increasing number of clinical trials, increasing favorable government funding, rise in the personalized medicines for the treatment, the increasing awareness among patients and healthcare professionals, rise in world population, growing adoption of inorganic growth strategies, and immense potential for emerging submarkets.

Rising Incidence of Hematologic Malignancies

Blood cancers are the fifth most common malignancy across the world and the second primary reason for cancer death. The growing prevalence of blood-related cancers such as myeloma, leukemia, and lymphoma, are augmenting the growth of the market. For instance, above 300,000 people are diagnosed annually with leukemia and 400,000 with lymphoma across the globe. Owing to the rise in number of cases suffering from hematologic malignancies, the surge in demand for MRD testing is fueling the growth of the market. According to the American Cancer Society, in the United States, around every 3 minutes, a person is diagnosed with leukemia, lymphoma, and myeloma.

Growing Awareness among Physicians and Consumers

Tailored therapies are basically personalized medicines which provide successful treatments by targeting proteins which control how the cancer cells spread, divide, and grow. Nowadays, people are becoming more aware about the tailored therapy, which is a contributing factor for the growth of the market. The increasing awareness among people to confirm the presence of carcinogens is also a key factor. Furthermore, growing awareness among physicians to use MRD testing for the treatment of various type of cancer, especially blood cancers is driving the growth of the market.

Technological Advancements and Rise in R&D activities

Rapid advancement in technology such as next generation sequencing (NGS)-based clonoSEQ assay and low-cost PCR are propelling the growth of the market. Owing to recent developments in molecular diagnostic technologies, the reduction in time and overall cost with increased sensitivity and accuracy of results is facilitating the growth of the market. For instance, in 2020, Creative Diagnostics launched a Real-Time Quantitative PCR Kit for Minimal Residual Disease (MRD). In addition, growing R&D activities are propelling the growth of the market.  For instance, in 2022, Invitae Corporation, U.S. based company, started research to collect authentic data on tailored minimal residual disease diagnostics for tumor types.


Download Free Sample Report

Market Segmentation

The global minimal residual disease (MRD) testing market is segmented into technology, application, end user, and company. Based on technology, the market is divided into flow cytometry, polymerase chain reaction, next generation sequencing, and others. Based on application, the market is divided into leukemia, lymphoma, multiple myeloma, and others. Based on end user, the market is divided into hospitals & specialty clinics, academic & research institutions, clinical laboratories, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due rising incidences of hematologic malignancies in the country.

Market Players

ICON plc, F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Cergentis B.V., OPKO Health, Inc., Sysmex Corporation, Mission Bio, Inc., and Invivoscribe, Inc. are some of the leading companies operating in the market.

Attribute

Details

Base Year

2021

Historic Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, Volume Units and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends

Segments covered

·         Technology

·         Application

·         End User

·         Company

Regional scope

North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; China; India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa;

Key companies profiled

ICON plc, F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Cergentis B.V., OPKO Health, Inc., Sysmex Corporation, Mission Bio, Inc., and Invivoscribe, Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, global minimal residual disease (MRD) testing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

·         Minimal Residual Disease (MRD) Testing Market, By Technology:

o   Flow Cytometry

o   Polymerase Chain Reaction

o   Next Generation Sequencing

o   Others

·         Minimal Residual Disease (MRD) Testing Market, By Application:

    • Leukemia
    • Lymphoma
    • Multiple Myeloma
    • Others

·         Minimal Residual Disease (MRD) Testing Market, By End User:

o   Hospitals & Specialty Clinics

o   Academic & Research Institutions

o   Clinical Laboratories

o   Others

·         Minimal Residual Disease (MRD) Testing Market, By Region:

    • North America
      • United States
      • Canada
      • Mexico
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
    • Europe & CIS
      • Germany
      • France
      • United Kingdom
      • Spain
      • Italy
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Minimal Residual Disease (MRD) Testing Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Minimal Residual Disease (MRD) Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

2.    Research Methodology

3.    Executive Summary

4.    Impact of COVID-19 on Global Minimal Residual Disease (MRD) Testing Market

5.    Voice of Customer

6.    Global Minimal Residual Disease (MRD) Testing Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, Others)

6.2.2.     By Application (Leukemia, Lymphoma, Multiple Myeloma, Others)

6.2.3.     By End User (Hospitals & Specialty Clinics, Academic & Research Institutions, Clinical Laboratories, Others)

6.2.4.     By Region

6.2.5.     By Company (2021)

6.3.  Market Map

7.    North America Minimal Residual Disease (MRD) Testing Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Technology

7.2.2.     By Application

7.2.3.     By End User

7.2.4.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Minimal Residual Disease (MRD) Testing Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Technology

7.3.1.2.2.             By Application

7.3.1.2.3.             By End User

7.3.2.     Canada Minimal Residual Disease (MRD) Testing Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Technology

7.3.2.2.2.             By Application

7.3.2.2.3.             By End User

7.3.3.     Mexico Minimal Residual Disease (MRD) Testing Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Technology

7.3.3.2.2.             By Application

7.3.3.2.3.             By End User

8.    Europe Minimal Residual Disease (MRD) Testing Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Technology

8.2.2.     By Application

8.2.3.     By End User

8.2.4.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Minimal Residual Disease (MRD) Testing Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Technology

8.3.1.2.2.             By Application

8.3.1.2.3.             By End User

8.3.2.     Germany Minimal Residual Disease (MRD) Testing Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Technology

8.3.2.2.2.             By Application

8.3.2.2.3.             By End User

8.3.3.     United Kingdom Minimal Residual Disease (MRD) Testing Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Technology

8.3.3.2.2.             By Application

8.3.3.2.3.             By End User

8.3.4.     Italy Minimal Residual Disease (MRD) Testing Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Technology

8.3.4.2.2.             By Application

8.3.4.2.3.             By End User

8.3.5.     Spain Minimal Residual Disease (MRD) Testing Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Technology

8.3.5.2.2.             By Application

8.3.5.2.3.             By End User

9.    Asia-Pacific Minimal Residual Disease (MRD) Testing Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Technology

9.2.2.     By Application

9.2.3.     By End User

9.2.4.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Minimal Residual Disease (MRD) Testing Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Technology

9.3.1.2.2.             By Application

9.3.1.2.3.             By End User

9.3.2.     India Minimal Residual Disease (MRD) Testing Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Technology

9.3.2.2.2.             By Application

9.3.2.2.3.             By End User

9.3.3.     Japan Minimal Residual Disease (MRD) Testing Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Technology

9.3.3.2.2.             By Application

9.3.3.2.3.             By End User

9.3.4.     South Korea Minimal Residual Disease (MRD) Testing Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Technology

9.3.4.2.2.             By Application

9.3.4.2.3.             By End User

9.3.5.     Australia Minimal Residual Disease (MRD) Testing Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Technology

9.3.5.2.2.             By Application

9.3.5.2.3.             By End User

10.  South America Minimal Residual Disease (MRD) Testing Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Technology

10.2.2.  By Application

10.2.3.  By End User

10.2.4.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Minimal Residual Disease (MRD) Testing Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Technology

10.3.1.2.2.           By Application

10.3.1.2.3.           By End User

10.3.2.  Argentina Minimal Residual Disease (MRD) Testing Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Technology

10.3.2.2.2.           By Application

10.3.2.2.3.           By End User

10.3.3.  Colombia Minimal Residual Disease (MRD) Testing Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Technology

10.3.3.2.2.           By Application

10.3.3.2.3.           By End User

11.  Middle East and Africa Minimal Residual Disease (MRD) Testing Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Technology

11.2.2.  By Application

11.2.3.  By End User

11.2.4.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Minimal Residual Disease (MRD) Testing Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Technology

11.3.1.2.2.           By Application

11.3.1.2.3.           By End User

11.3.2.  Saudi Arabia Minimal Residual Disease (MRD) Testing Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Technology

11.3.2.2.2.           By Application

11.3.2.2.3.           By End User

11.3.3.  UAE Minimal Residual Disease (MRD) Testing Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Technology

11.3.3.2.2.           By Application

11.3.3.2.3.           By End User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape (Inclusive SWOT Analysis)

14.1.              ICON plc

14.2.              F. Hoffmann-La Roche AG

14.3.              Bio-Rad Laboratories, Inc.

14.4.              Laboratory Corporation of America Holdings

14.5.              Natera, Inc.

14.6.              Cergentis B.V.

14.7.              OPKO Health, Inc.

14.8.              Sysmex Corporation

14.9.              Mission Bio, Inc.

14.10.            Invivoscribe, Inc.

15.  Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Growing incidence of blood cancers, rise in number of patients, and rising technological advancements are driving the demand for the global minimal residual disease (MRD) testing market.

down-arrow

ICON plc, F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Cergentis B.V., OPKO Health, Inc., Sysmex Corporation, Mission Bio, Inc., and Invivoscribe, Inc. are the key players operating in the global Minimal Residual Disease (MRD) testing market.

down-arrow

The uncertain reimbursement and regulatory policies, lack of trained professionals, and lack of established treatment protocols for high-value tests in emerging economies may hamper the growth of the global minimal residual disease (MRD) testing market.

down-arrow

The Asia-Pacific is expected to register the highest CAGR during the forecast period.

profile

Sakshi Bajaal

Business Consultant
Press Release

Minimal Residual Disease (MRD) Testing Market to be dominated by Rising Awareness among Patients and Physicians through 2027

Sep, 2022

Growing incidences of hematologic malignancies to drive the minimal residual disease (MRD) testing market in the forecast period, 2023-2027.